Depression follow-up monitoring with the PHQ-9: open cluster-randomised controlled trial.
Kendrick T, Dowrick C, Lewis G, Moore M, Leydon G, Geraghty AWA, Griffiths G, Zhu S, Yao G, May C, Gabbay M, Dewar-Haggart R, Williams S, Bui L, Thompson N, Bridewell L, Trapasso E, Patel T, McCarthy M, Khan N, Page H, Corcoran E, Hahn JS, Bird M, Logan MX, Ching BCF, Tiwari R, Hunt A, Stuart B.
Kendrick T, et al.
Br J Gen Pract. 2024 Feb 26:BJGP.2023.0539. doi: 10.3399/BJGP.2023.0539. Online ahead of print.
Br J Gen Pract. 2024.
PMID: 38408790
SECONDARY OUTCOMES: BDI-II at 26 weeks; Work and Social Adjustment Scale and EuroQol EQ-5D-5L quality of life at 12 and 26 weeks; antidepressant treatment, mental health service use, adverse events, and Medical Informant Satisfaction Scale over 26 weeks. ...There was no si …
SECONDARY OUTCOMES: BDI-II at 26 weeks; Work and Social Adjustment Scale and EuroQol EQ-5D-5L quality of life at 12 and 26 weeks; ant …